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“Take home” message / Abstract 
CTEPH patients over 80 years old undergoing pulmonary endarterectomy have 
similar outcomes to those under 80. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To the Editor: 
 
Pulmonary endarterectomy (PEA) is the treatment of choice in operable chronic 
thromboembolic pulmonary hypertension (CTEPH) with excellent long term 
outcomes [1].  It is a complex surgical procedure requiring cardiopulmonary bypass 
and removal of obstructive thromboembolic material during periods of deep 
hypothermic circulatory arrest [1].  We have observed an increase in the number of 
older CTEPH patients referred for consideration of PEA, which is consistent with 
other cardiothoracic surgeries.  The UK population is aging with a projected 3% 
increase in those over 85 years in the next 20 years [2].  This may be mirrored by 
patients with CTEPH getting older, as the incidence of pulmonary embolism, which 
frequently precedes CTEPH, increases markedly with age [3,4].  Furthermore, an 
epidemiological analysis by Gall et al, has projected that the annual incidence of 
CTEPH will increase over the next 10 years [5].  Therefore, the management of 
CTEPH in older patients is a pertinent topic for investigation.            
 
We previously reported that hospital survival in patients over 70 years undergoing 
PEA was comparable to those under 70, albeit with longer hospital and intensive 
care unit (ICU) stays [6].  For selected cardiac surgeries (coronary artery bypass and 
aortic valve surgery) octogenarians have equivalent or improved long-term mortality 
compared to an age- and sex-matched population [7,8].  Furthermore, patient 
reported outcomes (PROs) including quality of life improve post-operatively, and are 
equivalent or better than a matched general population of octogenarians [7,9].  
However, increased in-hospital mortality and prolonged hospital / ICU length of stay 
have also been reported, which may translate to increased health utilisation costs 
[10,11].  Therefore, in the current study, we aimed to assess the outcomes of 
CTEPH patients over 80 years old who underwent PEA. 
     
Consecutive CTEPH patients undergoing PEA from June 2006 to August 2016 at the 
UK National PEA centre (Papworth, UK) were included in a retrospective analysis.  
The diagnosis of CTEPH was based on international criteria [12].  Suitability for PEA 
was discussed by a multidisciplinary team comprising pulmonary hypertension 
physicians, specialist cardiothoracic radiologists and pulmonary endarterectomy 
surgeons.  The cohort was dichotomized into over and under 80 years according to 
the age at time of surgery.  Pre-operative baseline and post-operative 3-6-month 
follow-up data were recorded, with follow-up data included until 3 months after the 
end of the census period. PROs were assessed using the Cambridge Pulmonary 
Hypertension Outcome Review (CAMPHOR) score, a PH specific quality of life 
measure [13].  Groups were compared using a chi-squared test for categorical data, 
Wilcoxon rank-sum test for continuous data and log-rank test for survival data.  A 
false discovery rate adjusted p-value was used to account for multiple testing. 
   
1152 individuals underwent PEA (under 80 years: 1115 (97%); over 80: 37 (3%)) 
during the study period.  Baseline and 3-6 month follow-up variables and outcomes 
are summarised in table 1. Overall survival at 1, 3 and 5 years was 91.8%, 88.2% 
and 84.4% in the under 80 group, and 83.5%, 76.4% and 69.4% in the over 80 
group.  Whilst survival was lower in the over 80 group (Log-rank test, p=0.020), it 
was no different from an age- and sex-matched UK reference population (p=0.500) 
[15].  
 
There were significant improvements in World Health Organisation (WHO) functional 
class, 6-minute walk distance (6mwd) and haemodynamics for both under and over 
80s post-PEA.  Whilst the 6mwd was lower in the over 80s post-PEA (286±164 vs. 
360±92; p=0.020) there was an equivalent change from baseline (p=0.676) reflecting 
the same magnitude of improvement.  Furthermore, there was no difference in the 
median change from baseline for WHO functional class, haemodynamics or PROs 
between under and over 80s, indicating an equivalent improvement in outcomes.   
 
There were more concomitant cardiac surgical procedures in the over 80 group (11% 
vs. 27% p= 0.042), predominantly due to more coronary artery bypass grafts (7% vs. 
19%).  There was a shorter cardiopulmonary bypass time (323±305 minutes vs. 
305±65; p=0.020) in the over 80s but no difference in the total deep hypothermic 
circulatory arrest time or type of surgical disease (Jamieson classification based on 
location and morphology) (p=0.230 and p=1.000).  The hospital length of stay was 
longer in those over 80 (19±7 vs. 14±10 days; p=0.020) but there was no difference 
in time spent on the ICU (4±3 vs. 5±5 days; p=0.310).  There was also no difference 
in post-PEA complications (p=1.000) or in hospital mortality (4% vs. 8%; p=0.510).     
 
Despite the study limitations (small group size of over 80s, retrospective single-
centre analysis), we found similar outcomes in patients under and over 80 years old 
undergoing PEA, except for a prolonged hospital length of stay in octogenarians.  
Whilst survival is reduced in the over 80 group compared to the under 80s, it is no 
different to a reference age- and sex-matched UK population.  The greater number 
of concomitant cardiac surgeries in octogenarians could indicate that their 
improvement is multi-factorial.  Future research should consider the health utilization 
and cost implications of older patients undergoing PEA, given they have a prolonged 
hospital length of stay.    
 
We acknowledge that CTEPH patients over 80 were highly selected to undergo PEA 
and therefore our results may not apply to “all comers”.  However, it reinforces the 
effectiveness of the PEA selection process at expert centres.  Age alone should not 
be a contraindication for PEA and individuals with suspected CTEPH should be 
referred for specialist evaluation.     
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TABLE 1 
Baseline variables and post-PEA outcomes subdivided by age cohorts. 
 
 
Baseline Follow-up 
Under 80 Over 80 p-value Under 80 Over 80 p-value 
Subjects (n)  1115 37     
Age at PEA [years] 61 (22) 81 (2)     
Gender [female] 517 (46) 17 (46) 1.000    
Comorbidities 
COPD 
Diabetes 
Atrial fibrillation/flutter 
Ischaemic heart disease 
Malignancy 
Systemic hypertension 
78 (7) 
94 (9) 
91 (9) 
124 (12) 
85 (8) 
307 (30) 
2 (5) 
2 (6) 
5 (14) 
7 (19) 
4 (11) 
10 (28) 
1.000 
0.950 
0.810 
0.560 
1.000 
1.000 
   
CAMPHOR scorea: 
 
Symptoms 
Activity 
Quality of life 
13 ± 10 
11 ± 9 
11 ± 11 
12 ± 9 
14 ± 8 
11 ± 11 
1.000 
0.260 
0.870 
4 ± 8 
6 ± 9 
4 ± 10 
4 ± 7 
9 ± 6 
6 ± 8 
0.860 
0.300 
1.000 
WHO functional class [1/2/3/4 (%)]b 0 / 14/ 73/ 13 0/ 3/ 70/ 26 0.046 28/ 47/ 23/ 1 22/ 40/ 33/ 4 0.450 
6mwd [metres] 290 ± 216 227 ± 210 0.051 360 ± 164 286 ± 92 0.020 
mPAP [mmHg] 45 ± 15 42 ± 12 0.560 25 ± 13 28 ± 12 0.560 
PVR [dynes.s.cm-5]
 
 666 ± 479 743 ± 462 0.310 235 ± 212 297 ± 294 0.081 
CI [L/min/m2] 2.2 ± 0.8 1.9 ± 0.8 0.020 2.3 ± 0.7 2.3 ± 0.8 0.810 
Type of surgical diseasec [1/2/3/4 (%)] 14/ 58/ 26/ 3 14/ 59/ 27/ 0 1.000    
Bypass time [mins] 323 ± 65 305 ± 51 0.020    
Arrest time [mins] 37 ± 15 33 ± 13 0.230    
Concomitant surgery: Total 
CABG 
PFO/ASD closure 
MVR 
AVR 
123 (11) 
76 (7) 
34 (3) 
12 (2) 
8 (1) 
10 (27) 
7 (19) 
1 (3) 
0 (0) 
2 (5) 
0.042 
 
 
 
 
   
Complications: Totald 
ECMO 
Pneumonia 
Re-intubation 
Renal replacement therapy 
Return to theatre 
Tracheotomy 
277 (32) 
60 (6) 
110 (12) 
91 (10) 
52 (6) 
80 (9) 
61 (6) 
12 (35) 
2 (6) 
6 (18) 
3 (9) 
0 (0) 
2 (6) 
1 (3) 
1.000 
 
 
 
 
 
 
   
Length of stay [days] 
Intensive care unit 
Total hospital 
4 ± 3 
14 ± 10 
5 ± 5 
19 ± 7 
0.310 
0.020 
   
In-hospital mortality [%] 4 8 0.510    
Residual PHe 
mPAP25mmHg 
mPAP30mmHg 
mPAP38mmHg and 
PVR425dynes.s.cm-5 
   
 
463 (51) 
309 (34) 
 
101 (11) 
 
18 (62) 
13 (44) 
 
2 (7) 
 
1.000 
0.560 
 
0.930 
Survival [%] 
1 year 
3 years 
5 years 
  
 
91.8 
88.2 
84.4 
83.5 
76.4 
69.4 
 
0.020 
 
 
 
Data presented as median ± Interquartile range or number of patients (%) unless otherwise stated.  6mwt: 6-minute walk distance; AVR: 
aortic valve replacement; CABG: coronary artery bypass graft; CAMPHOR: Cambridge Pulmonary Hypertension Outcome Review 
score; CI: cardiac index; ECMO: Extracorporeal membrane oxygenation; mPAP: mean pulmonary arterial pressure; MVR: mitral valve 
replacement; PFO/ASD: patent foramen ovale / atrial septal defect; PH: pulmonary hypertension; PVR: pulmonary vascular resistance; 
WHO: World Health Organisation. 
a CAMPHOR score: a higher score denotes a worse patient reported outcome 
b Total percentage may not add up to 100 due to rounding  
c Jamieson classification 
d Total: any of the listed complications   
e The higher residual PH thresholds have been associated with post-PEA outcomes [14] 
 
 
